Patents by Inventor Sander G. Mills

Sander G. Mills has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FK-506 C10-C18 process intermediates
    Patent number: 5155228
    Abstract: A process is described for the improved synthesis of the optically pure C.sub.10 -C.sub.18 fragment of the macrolide structure of the immunosuppressant FK-506. This compound is also useful as an intermediate for preparing FK-506 derivatives.
    Type: Grant
    Filed: May 16, 1991
    Date of Patent: October 13, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Todd K. Jones, Sander G. Mills, Richard Desmond
  • Processes and intermediates for the preparation of 5-oxygenated HMG-CoA reductase inhibitors
    Patent number: 5059696
    Abstract: This invention discloses novel intermediates and novel process for their preparation where said intermediates are useful for the preparation of 5-oxygenated derivatives (T) of lovastatin and analogs thereof at the 8-acyl side chain and 6-position of the polyhydronaphthyl ring. Said derivatives of lovastatin (T) and analogs thereof are useful in treating hypercholesterolemia and are disclosed in the U.S. Pat. No. 4,963,538.
    Type: Grant
    Filed: March 15, 1990
    Date of Patent: October 22, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Anderson, Ann E. DeCamp, Alan T. Kawaguchi, Anthony O. King, Sander G. Mills, Ralph P. Volante
  • Process for synthesis of 1R,2R,5R-2-hydroxy-6-oxo-7-oxabicyclo[3.2.1]-octane
    Patent number: 4940803
    Abstract: A process is described for the synthesis of hydroxy lactone 3, being 1R, 2R, 5R-2-hydroxy-6-oxo-7-oxabicyclo[3.2.1]-octane, in optically pure form, which is useful as an intermediate in the synthesis of the C.sub.20 -C.sub.34 chain of the macrolide structure for the immunosuppressant FK-506. This compound is also useful as a precursor for producing an ultraviolet radiation absorber.
    Type: Grant
    Filed: May 23, 1988
    Date of Patent: July 10, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Sander G. Mills, Ralph P. Volante, Ichiro Shinkai
  • Process for synthesis of FK-506 C10-C18 intermediates
    Patent number: 4940797
    Abstract: A process is described for the improved synthesis of the optically pure C.sub.10 -C.sub.18 fragment of the macrolide structure of the immunosuppressant FK-506. This compound is also useful as an intermediate for preparing FK-506 derivatives.
    Type: Grant
    Filed: March 23, 1989
    Date of Patent: July 10, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Todd K. Jones, Sander G. Mills, Richard Desmond
  • Process for synthesis of E-2-methyl-.alpha.,.beta.-unsaturated aldehydes
    Patent number: 4914220
    Abstract: A process is described for the synthesis of E-2-methyl-.alpha.,.beta.-unsaturated aldehydes, which are useful as intermediates in the synthesis of the macrolide structure of the immunosuppressant FK-506. These compounds are also useful as ultraviolet radiation absorbers.
    Type: Grant
    Filed: February 27, 1989
    Date of Patent: April 3, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Richard Desmond, Sander G. Mills, Ralph P. Volante, Ichiro Shinkai
  • Process for synthesis of arylglyoxal arylimines
    Patent number: 4871873
    Abstract: A process for producing arylglyoxal arylimine intermediates, by the DMSO/HBr oxidation of arylmethylketones. The imine compounds are intermediates in the synthesis of carbapenem antibiotics, i.e. imipenem.
    Type: Grant
    Filed: March 18, 1988
    Date of Patent: October 3, 1989
    Assignee: Merck & Company Incorporated
    Inventors: Richard Desmond, Sander G. Mills, Ralph P. Volante, Ichiro Shinkai